India · Delayed Price · Currency is INR Best Agrolife Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw a 31% revenue decline due to adverse weather, inventory buildup, and input cost volatility, but gross margin improved to 30%. Patented products now make up 40% of branded sales, and management expects improved profitability in FY 2027 with new launches and tighter working capital control.
-
Q3 FY26 saw revenue and profit declines due to adverse weather and high generic inventory, but patented products and operational improvements provided resilience. Management expects stabilization in FY26 and a return to growth and higher margins from FY27, with international expansion and new product launches as key drivers.
-
Q2 and H1 FY2026 saw revenue and margins decline due to adverse weather, but operational discipline, inventory reduction, and a shift to patented products improved resilience. Management guides for INR 1,500 crore turnover and 13%-14% EBITDA margin for FY2026, with a positive Rabi outlook.
-
Q1 FY26 saw a 25%-27% YoY revenue decline to INR 382 crore, but gross margin rose to 30% and EBITDA margin to 12% due to a focus on patented products and operational efficiency. FY26/27 revenue is guided at INR 1,600-1,700 crore with EBITDA margin above 15%.
Fiscal Year 2025
-
Q4 FY25 saw a strong operational turnaround with revenue up 103% year-over-year and losses sharply reduced. Focus remains on branded, patented products, margin improvement, and cash flow, with INR 150 crore expected from new launches and EBITDA margin targeted at 15-18% for FY26.
-
Q3 FY2025 saw revenue and profitability decline due to adverse weather, weak crop prices, and high sales returns, despite improved gross margins from branded products. Management is focused on cost optimization, operational agility, and leveraging new patents and partnerships for future growth.
-
Q2 FY25 saw strong branded product growth and margin expansion, despite lower overall revenue due to reduced institutional sales and price cuts. The company expects robust sales in H2, driven by new patented launches, a strong Rabi season, and improved financial metrics.
-
Revenue and profitability declined year-over-year due to a strategic shift to branded products, high-cost inventory, and price competition, but management expects improved margins and growth in upcoming quarters as new patented products gain traction and inventory is liquidated.